Market closedNon-fractional
Immunome/IMNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Immunome
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Ticker
IMNM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bothell, United States
Employees
62
Website
immunome.com
Immunome Metrics
BasicAdvanced
$961M
Market cap
-
P/E ratio
-$7.82
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$961M
Beta
1.88
Financial strength
Current ratio
10.184
Quick ratio
10.066
Long term debt to equity
0.422
Total debt to equity
0.569
Management effectiveness
Return on assets (TTM)
-15.16%
Return on equity (TTM)
-154.98%
Valuation
Price to revenue (TTM)
37.518
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-10.389
Growth
Revenue change (TTM)
436.51%
Earnings per share change (TTM)
214.84%
3-year earnings per share growth (CAGR)
33.30%
What the Analysts think about Immunome
Analyst Ratings
Majority rating from 6 analysts.
Immunome Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-73.68%
Net income
-$129M
39.74%
Profit margin
-12,940.00%
431.02%
Immunome Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.46
-$4.22
-$2.51
-
Expected
$0.59
-$0.16
-$0.28
-$0.69
-$0.39
Surprise
-159.83%
187.50%
1,389.41%
261.78%
-
Immunome News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunome stock?
Immunome (IMNM) has a market cap of $961M as of July 27, 2024.
What is the P/E ratio for Immunome stock?
The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of July 27, 2024.
Does Immunome stock pay dividends?
No, Immunome (IMNM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Immunome dividend payment date?
Immunome (IMNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunome?
Immunome (IMNM) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Immunome stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.